胰腺腺癌的危险因素及筛查前景
Risk factors for pancreatic adenocarcinoma and prospects for screening.
作者信息
Decker G Anton, Batheja Mashal J, Collins Joseph M, Silva Alvin C, Mekeel Kristin L, Moss Adyr A, Nguyen Cuong C, Lake Douglas F, Miller Laurence J
出版信息
Gastroenterol Hepatol (N Y). 2010 Apr;6(4):246-54.
Abstract
Pancreatic cancer has one of the worst survival rates of any cancer and is the fourth leading cause of cancer mortality. Early detection and surgery are the patient's best chance for cure. However, symptoms are typically vague and occur when the cancer is unresectable. Population-based mass screening is not practical for this rare disease, though screening and early detection in asymptomatic high-risk patient populations may be indicated.
摘要
胰腺癌是所有癌症中生存率最差的癌症之一，是癌症死亡的第四大主要原因。早期检测和手术是患者治愈的最佳机会。然而，症状通常不明确，且在癌症无法切除时才会出现。基于人群的大规模筛查对于这种罕见疾病并不实际，不过对于无症状的高危患者群体进行筛查和早期检测可能是有必要的。
相似文献
1
Risk factors for pancreatic adenocarcinoma and prospects for screening.
Gastroenterol Hepatol (N Y). 2010 Apr;6(4):246-54.
2
[Precancerous conditions and risk factors for pancreatic and bile duct cancer].
Klin Onkol. 2013;26 Suppl:S29-33. doi: 10.14735/amko2013s29.
3
Early detection of pancreatic cancer.
Chin J Cancer Res. 2015 Aug;27(4):321-31. doi: 10.3978/j.issn.1000-9604.2015.07.03.
5
Pancreatic cancer: clinical presentation, pitfalls and early clues.
Ann Oncol. 1999;10 Suppl 4:140-2.
6
Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
JAMA. 2019 Aug 6;322(5):445-454. doi: 10.1001/jama.2019.6190.
7
The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report.
J Med Case Rep. 2019 Jun 11;13(1):178. doi: 10.1186/s13256-019-2125-5.
8
Optimizing cancer cure dialog: an analysis of pancreatic cancer patients' views regarding survival and cure.
Support Care Cancer. 2020 Aug;28(8):3731-3737. doi: 10.1007/s00520-019-05214-0. Epub 2019 Dec 10.
9
Epidemiology of pancreatic adenocarcinoma.
Chin Clin Oncol. 2017 Jun;6(3):24. doi: 10.21037/cco.2017.06.32.
10
Pancreatic cancer screening: Still a delusion?
Pancreatology. 2017 Sep-Oct;17(5):754-765. doi: 10.1016/j.pan.2017.07.001. Epub 2017 Jul 13.
引用本文的文献
1
Quantitative Metabolomics and Lipoprotein Analysis of PDAC Patients Suggests Serum Marker Categories for Pancreatic Function, Pancreatectomy, Cancer Metabolism, and Systemic Disturbances.
J Proteome Res. 2024 Apr 5;23(4):1249-1262. doi: 10.1021/acs.jproteome.3c00611. Epub 2024 Feb 26.
2
Cyfra 21.1: A Useful Tumour Marker in Pancreatic Ductal Adenocarcinoma: Cross-Sectional Study.
Cancer Control. 2024 Jan-Dec;31:10732748241228037. doi: 10.1177/10732748241228037.
3
Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm.
Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188851. doi: 10.1016/j.bbcan.2022.188851. Epub 2022 Dec 16.
4
Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer.
J Biomed Inform. 2022 Jul;131:104095. doi: 10.1016/j.jbi.2022.104095. Epub 2022 May 20.
5
Current State of "Omics" Biomarkers in Pancreatic Cancer.
J Pers Med. 2021 Feb 14;11(2):127. doi: 10.3390/jpm11020127.
6
Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.
Cell Oncol (Dordr). 2020 Aug;43(4):539-575. doi: 10.1007/s13402-020-00519-3. Epub 2020 Jun 2.
7
Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188318. doi: 10.1016/j.bbcan.2019.188318. Epub 2019 Oct 30.
8
An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer.
Cancers (Basel). 2019 Jan 29;11(2):155. doi: 10.3390/cancers11020155.
9
LncRNA BC032020 suppresses the survival of human pancreatic ductal adenocarcinoma cells by targeting ZNF451.
Int J Oncol. 2018 Apr;52(4):1224-1234. doi: 10.3892/ijo.2018.4289. Epub 2018 Feb 28.
10
How early can pancreatic cancer be recognized? A case report and review of the literature.
Case Rep Oncol. 2015 Feb 3;8(1):46-9. doi: 10.1159/000375121. eCollection 2015 Jan-Apr.
本文引用的文献
1
Analysis of the plasma peptidome from pancreas cancer patients connects a peptide in plasma to overexpression of the parent protein in tumors.
J Proteome Res. 2009 Oct;8(10):4722-31. doi: 10.1021/pr900414f.
2
Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT.
J Magn Reson Imaging. 2009 Sep;30(3):586-95. doi: 10.1002/jmri.21889.
3
Magnetic resonance imaging of adenocarcinoma of the pancreas.
Top Magn Reson Imaging. 2009 Feb;20(1):3-9. doi: 10.1097/RMR.0b013e3181b48392.
4
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.
Am J Gastroenterol. 2009 Sep;104(9):2175-81. doi: 10.1038/ajg.2009.276. Epub 2009 Jun 2.
5
Cystic pancreatic lesions: classification and management.
J Am Coll Radiol. 2009 May;6(5):376-80. doi: 10.1016/j.jacr.2008.10.004.
6
Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy.
Pancreas. 2009 Jul;38(5):527-33. doi: 10.1097/MPA.0b013e3181a16d28.
7
Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults.
Radiology. 2009 Apr;251(1):175-84. doi: 10.1148/radiol.2511081296.
8
Pancreatic cancer screening: state of the art.
Expert Rev Gastroenterol Hepatol. 2009 Feb;3(1):89-96. doi: 10.1586/17474124.3.1.89.
9
Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature.
Mutat Res. 2009 Mar-Jun;681(2-3):299-307. doi: 10.1016/j.mrrev.2008.12.001. Epub 2008 Dec 27.
10
Multidisciplinary approach to diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas.
Clin Gastroenterol Hepatol. 2009 Mar;7(3):259-69. doi: 10.1016/j.cgh.2008.11.008. Epub 2008 Nov 13.
Zotero 插件